| Primary |
| Non-hodgkin's Lymphoma |
24.7% |
| Stem Cell Transplant |
12.2% |
| B-cell Lymphoma |
9.7% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii |
8.4% |
| Product Used For Unknown Indication |
7.9% |
| Lymphoma |
6.0% |
| Mantle Cell Lymphoma |
5.3% |
| Bone Marrow Conditioning Regimen |
4.5% |
| Diffuse Large B-cell Lymphoma |
3.7% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
3.7% |
| Drug Use For Unknown Indication |
3.4% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iii |
2.1% |
| Multiple Myeloma |
1.9% |
| Mantle Cell Lymphoma Recurrent |
1.4% |
| Central Nervous System Lymphoma |
1.2% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage I |
0.9% |
| Surgical Preconditioning |
0.9% |
| Non-hodgkin's Lymphoma Refractory |
0.8% |
| Asthma |
0.7% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) Stage Ii |
0.6% |
|
| White Blood Cell Count Decreased |
16.5% |
| Thrombocytopenia |
15.4% |
| Bone Marrow Failure |
9.1% |
| Pyrexia |
5.5% |
| Stem Cell Transplant |
5.0% |
| Sepsis |
4.4% |
| Vomiting |
4.4% |
| Septic Shock |
3.9% |
| Neutropenia |
3.6% |
| Pneumonia |
3.6% |
| Non-hodgkin's Lymphoma |
3.3% |
| Platelet Count Decreased |
3.3% |
| Pancytopenia |
3.0% |
| Sinusitis |
3.0% |
| Weight Decreased |
3.0% |
| Death |
2.8% |
| Nausea |
2.8% |
| Respiratory Failure |
2.8% |
| Renal Failure Acute |
2.5% |
| Progressive Multifocal Leukoencephalopathy |
2.2% |
|
| Secondary |
| Non-hodgkin's Lymphoma |
15.9% |
| B-cell Lymphoma |
14.4% |
| Drug Use For Unknown Indication |
10.0% |
| B-cell Lymphoma Recurrent |
9.9% |
| Product Used For Unknown Indication |
9.6% |
| Stem Cell Transplant |
7.4% |
| Diffuse Large B-cell Lymphoma |
6.6% |
| Lymphoma |
5.0% |
| Premedication |
3.0% |
| Mantle Cell Lymphoma |
2.6% |
| Prophylaxis |
2.4% |
| Multiple Myeloma |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
1.5% |
| Neutropenic Sepsis |
1.5% |
| Non-hodgkin's Lymphoma Stage Iv |
1.5% |
| Non-hodgkin's Lymphoma Recurrent |
1.5% |
| Hyperthermia |
1.3% |
| Immunosuppression |
1.2% |
| Bone Marrow Conditioning Regimen |
1.2% |
|
| White Blood Cell Count Decreased |
15.9% |
| Thrombocytopenia |
10.1% |
| Myelodysplastic Syndrome |
8.2% |
| Sepsis |
7.2% |
| Progressive Multifocal Leukoencephalopathy |
5.3% |
| Stevens-johnson Syndrome |
5.3% |
| Acute Myeloid Leukaemia |
4.3% |
| Acute Myelomonocytic Leukaemia |
4.3% |
| Bone Marrow Failure |
4.3% |
| Neutropenia |
4.3% |
| B-cell Lymphoma |
3.8% |
| Pyrexia |
3.8% |
| Septic Shock |
3.8% |
| Pneumonia |
3.4% |
| Renal Failure |
3.4% |
| Laryngeal Cancer |
2.9% |
| Neoplasm Malignant |
2.4% |
| Neutrophil Count Decreased |
2.4% |
| Pancytopenia |
2.4% |
| Renal Failure Acute |
2.4% |
|
| Concomitant |
| B-cell Lymphoma |
29.2% |
| Diffuse Large B-cell Lymphoma |
13.0% |
| Drug Use For Unknown Indication |
10.6% |
| Product Used For Unknown Indication |
7.4% |
| Lymphoma |
6.9% |
| Non-hodgkin's Lymphoma |
5.6% |
| Lymphocytic Lymphoma |
3.7% |
| Multiple Myeloma |
3.7% |
| Thrombocytopenia |
3.7% |
| Mantle Cell Lymphoma |
2.8% |
| Rheumatoid Arthritis |
2.8% |
| Anaemia Of Malignant Disease |
1.9% |
| Chronic Lymphocytic Leukaemia |
1.9% |
| Prophylaxis |
1.9% |
| No Therapeutic Response |
1.4% |
| Colony Stimulating Factor Prophylaxis |
0.9% |
| Constipation |
0.9% |
| Premedication |
0.9% |
| B-cell Lymphoma Stage Iv |
0.5% |
| Cystitis |
0.5% |
|
| Progressive Multifocal Leukoencephalopathy |
17.9% |
| Neutropenia |
10.3% |
| Renal Failure |
7.7% |
| Acute Myeloid Leukaemia |
5.1% |
| Aplasia Pure Red Cell |
5.1% |
| Bone Marrow Failure |
5.1% |
| Myelodysplastic Syndrome |
5.1% |
| Pancytopenia |
5.1% |
| Pyrexia |
5.1% |
| Septic Shock |
5.1% |
| Vision Blurred |
5.1% |
| Blindness Unilateral |
2.6% |
| Confusional State |
2.6% |
| Disease Progression |
2.6% |
| Gastritis |
2.6% |
| Hypothermia |
2.6% |
| Metastatic Bronchial Carcinoma |
2.6% |
| Neoplasm Malignant |
2.6% |
| No Therapeutic Response |
2.6% |
| Pain |
2.6% |
|
